MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why SRTA Stock slipped -0.21% Today — RQD Quant Desk Flash
$4.75 -0.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.74
Strata Critical Medical Inc. (Class A) (SRTA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $420.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.74 (-0.23%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-5.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRTA)Realized 20D OHLCV Swing Band: ±7.8%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY SRTA SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (34% of score)
Altman Z-Score 5.58 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (21% of score)
FRED Regime × Technicals: 31% of 52W Range • RSI-14 at 36.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)
Capital intensity & 0% operating margin leave 15 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.53+0.2% Next Q
39
Q2 (-2Q)Grade D$4.54+2.6% Next Q
42
Q3 (-1Q)Grade D$4.66+1.9% Next Q
44
CurrentGrade D$4.75-5.9% Hist 90D α
47
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SRTA Turnaround Squeeze
While SRTA currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Clean SEC annual filing review with no major hidden accounting time-bombs.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.10) and Max Pain ($4.99) forces dealer call-delta covering toward $6.83.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SRTA Stock slipped -0.21% Today — RQD Quant Desk Flash
Strata Critical Medical Inc. (Class A) (SRTA) slipped -0.21% to $4.75, trading at 31% of its 52-week range ($3.95 – $6.5). Stretched risk/reward at 10x P/E (-7% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 31% of its 52-week range ($3.95 – $6.5) with RSI-14 at 36.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.8% around $4.75 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 20.9% gross margin and $0 annual free cash flow.
Live SRTA Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRTA)
- ✓Walkthrough of SRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.38%▼ DESCENDING CHANNEL
2026-10-30O $4.70H $4.75L $4.40C $4.75VOL 1.11M
RES: $6.19SUP: $4.08SMA50: $5.10SMA200: $5.10
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-0.8%/yr Implied 5Y Growth
vs. +34.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SRTA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SRTA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRTA)
Health Care Rank #410 of 1016
⚔️ AUNA vs SRTA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SRTA vs. AUNA, SBC, STLN, AHCO)
Industry: Medical/Nursing Services (29 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Strata Critical Medical Inc. (Class A) (SRTA) ranks #410 by composite RQD confidence (47/100, grade D) and #474 by equity capitalization ($420.2M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with SRTA at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SRTA
ACTIVE
Strata Critical Medical Inc. (Class A) | D | 47/100 | 10.2x | 20.9% | -7.1% | -0.21% | $420.2M | Benchmark Subject |
| AUNA Auna SA (Class A) | C- | 61/100 | — | — | — | +1.27% | $355.3M | /auna-vs-srta → |
| SBC SBC Medical Group Holdings Incorporated | B- | 71/100 | 11.5x | 73.3% | 63.1% | +4.40% | $585.2M | /sbc-vs-srta → |
| STLN Starling Oncology Inc. | D- | 37/100 | — | — | -35.0% | +0.15% | $677.7M | /stln-vs-srta → |
| AHCO AdaptHealth Corp. | D | 45/100 | — | 18.8% | 2.2% | -1.66% | $808.5M | /ahco-vs-srta → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001779128In its most recent audited fiscal period (FY2025, filed 2025-12-31), Strata Critical Medical Inc. (Class A) (SRTA) reported GAAP revenue of $197.1M (+34.3% vs. FY2024 revenue of $146.8M , and -12.5% cumulative change since FY2023) , GAAP net income of $41.3M, operating cash flow of -$48.9M, and free cash flow of -$58.5M (-75.3% YoY). On the balance sheet, SRTA closed FY2025 with $325.5M in total assets against $0 in total debt (Altman Z-Score: 5.58, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $197.1M | $41.3M | -$48.9M | -$58.5M | $325.5M | — |
| FY2024 (FY) | 2024-12-31 | $146.8M | -$27.3M | -$2.5M | -$33.4M | $256.7M | — |
| FY2023 (FY) | 2023-12-31 | $225.2M | -$56.1M | -$32.3M | -$32.3M | — | — |
3. SRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Strata Critical Medical Inc. (Class A) (NASDAQ: SRTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.75 (-0.21% 1D, market cap $420.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, SRTA ranks #410 in composite RQD confidence.
How does SRTA compare to AUNA and SBC in the Health Care sector?
Within the Health Care sector (Medical/Nursing Services), SRTA carries a Roarable D (47/100 RQD), trailing P/E of 10.2x, gross margin of 20.9%, and ROIC of -7.1%. By comparison, AUNA (Auna SA (Class A)) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $355.3M) and SBC (SBC Medical Group Holdings Incorporated) posts a B- grade (71/100 RQD, P/E 11.5x, ROIC 63.1%, cap $585.2M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SRTA?
Per SRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001779128), Strata Critical Medical Inc. (Class A) generated $197.1M in revenue (+34.3% YoY), $41.3M in net income, and -$58.5M in free cash flow against $325.5M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SRTA trading relative to its 50-day, 200-day, and 52-week technical levels?
SRTA last traded at $4.75 (-0.21% on volume of 1,246,553 shares), positioning the stock -6.86% below its 50-day simple moving average ($5.10) and -6.86% below its 200-day simple moving average ($5.10). Across its 52-week range of $3.95 to $6.50, SRTA sits at the 31.4% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($4.38 to $5.12).
SRTA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SRTA stock moving today?
Why SRTA Stock slipped -0.21% Today — RQD Quant Desk Flash. Stretched risk/reward at 10x P/E (-7% return on capital) under elevated 10-year interest-rate pressure.